Company’s third biosimilar expands access to proven targeted biologic therapy with patient-centric support services and resources
Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced the commercial launch of IMULDOSA (ustekinumab-srlf), a biosimilar to STELARA (ustekinumab). IMULDOSA prefilled syringes, which would represent the majority of the presentations in the ustekinumab market, are priced at the lowest wholesaler acquisition cost (WAC) among all branded ustekinumab biosimilars at a 92% discount from STELARA. FDA-approved for the same indications as the reference product, IMULDOSA represents Accord BioPharma’s third in-market biosimilar and furthers the company’s mission to expand patient access to potentially life-changing biologic therapies.¹ Accord BioPharma is committed to providing patients with greater access to ustekinumab through this significant cost reduction.
Health Technology Insights: Digital Startup Drive Health Announces Establishment of A Clinical Advisory Council
This IMULDOSA launch will lay the foundation for Accord BioPharma’s immunology franchise, demonstrating the company’s commitment to addressing critical needs in immune-mediated inflammatory conditions.
Addressing Critical Patient Needs in the U.S.
Millions of Americans suffer from chronic, immune-mediated inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. These conditions are often not only incredibly painful and debilitating, but can also impact a person’s quality of life, emotional well-being, and self-image. While biologics such as STELARA have had a transformative impact on the lives of many people in the U.S., they often come with a high cost that can prohibit access. Accord BioPharma’s ustekinumab biosimilar IMULDOSA has been proven to be highly similar to STELARA with no clinically meaningful differences.¹ Please see below for full Indications and Important Safety Information.
As Accord BioPharma prepared for the commercial launch of IMULDOSA, the company solicited feedback from their patient advisory board on the development of patient support materials. The company is grateful for their invaluable input in these co-creation sessions.
Health Technology Insights: Providers Express Frustration with Prior Authorization, Favor Real‑Time Tech Fix
Expanding Access for Eligible Patients
Accord BioPharma has priced IMULDOSA to maximize patient access across all formulations. The prefilled syringes feature the lowest WAC price among branded ustekinumab biosimilars at a 92% discount from STELARA, while the vial formulation offers a 33% discount.
Accord BioPharma is launching IMULDOSA with a $0 co-pay program for eligible patients so that more people living with plaque psoriasis, psoriatic arthritis, and Crohn’s disease and ulcerative colitis can receive a proven targeted biologic therapy.
“At Accord BioPharma, we believe that cost shouldn’t be a barrier to accessing proven, life-changing therapies,” said Chrys Kokino, Accord U.S. President. “The launch of IMULDOSA represents our commitment to going beyond simply providing biosimilar alternatives to delivering comprehensive solutions that can make a meaningful difference in patients’ lives. With our third biosimilar now available, we’re demonstrating that Accord BioPharma is at the forefront of biosimilar transformation, backed by the 50-year heritage of our parent company, Intas Pharmaceuticals.”
Backed by Proven Heritage and Commitment
Accord BioPharma believes deeply in the power of biosimilars to reshape the future of treatment. With the support of Intas, an established global leader with nearly five decades of experience, Accord BioPharma is transforming the conventional treatment landscape across several priority therapeutic areas by introducing biosimilars to the U.S. market.
“The launch of IMULDOSA in the United States represents our unwavering commitment to making high-quality, more cost-effective biologic therapies more accessible within immunology’s critical therapeutic areas,” said Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals. “Through Accord BioPharma, we are establishing ourselves in the U.S. as a trusted, reliable ally highly attuned to the needs of our stakeholders and dedicated to transforming patient care.”
Current Portfolio of Brands
Accord BioPharma’s portfolio has experienced sizable growth within the past year. In addition to launching IMULDOSA, Accord BioPharma recently assumed U.S. operations for the full UDENYCA (pegfilgrastim-cbqv) franchise, including the UDENYCA pre-filled syringe, the UDENYCA autoinjector, and UDENYCA ONBODY. The company is also marketing HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), and CAMCEVI (leuprolide) 42 mg injectable emulsion. Please refer to the Important Safety Information and full Prescribing Information for all products.
Intas Pharmaceuticals, Ltd. has an exclusive agreement with Bio-Thera Solutions to enable Accord BioPharma to bring Bio-Thera’s golimumab candidate BAT2506 – a biosimilar to Simponi (golimumab) – to the U.S. market, further expanding Accord BioPharma’s pipeline. Accord BioPharma has also submitted Biologics License Applications to the FDA for biosimilar versions of several other biologics.
Health Technology Insights: Lyra Health Study Finds AI Can Reduce Mental Health Care Costs Without Sacrificing Outcomes
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source- PR Newswire
